Clinical Outcomes of Recurrent Intracranial Meningiomas Treated with Proton Beam Reirradiation.
11/05/2019
/
Publications
/
Reirradiation
Toxicity
Survival
This is a retrospective analysis of 16 patients who received PBRT reRT for recurrent meningiomas. The median PBRT dose was 60 Gy(RBE) and the median follow-up...
Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma.
07/09/2019
/
Publications
/
Chemotherapy
Survival
A study by the Jacksonville group. Seventeen patients with nonmetastatic nasopharyngeal carcinoma underwent double-scattered proton therapy. With the median...
Radiation for ETMR: LR and case series of patients treated with PT.
11/11/2018
/
Publications
/
Survival
Embryonal tumors with multilayered rosettes (ETMRs) are aggressive tumors that typically occur in young children. This study reported the outcomes of seven...
Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients.
06/05/2024
/
Publications
/
Survival
This review included 10 studies representing 1,718 patients. A pooled analysis was performed to evaluate the relationship between lymphopenia and overall...
Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry.
31/01/2021
/
Publications
/
Survival
44 patients with high-risk (n = 39) or intermediate-risk (n = 5) neuroblastoma were treated with protons. With a median follow-up of 27.6 months, eight patients...
Proton Therapy for Pediatric Ependymoma: Mature Results from a Bicentric Study.
01/07/2021
/
Publications
/
Survival
Toxicity
386 children with nonmetastatic grade II/III intracranial ependymoma received proton therapy. With the median follow-up of 5 years, the 7-year local control...
Radiation-induced brain injury in patients with meningioma treated with proton or photon therapy.
13/05/2021
/
Publications
/
Survival
77 patients (38 proton and 39 photon) were evaluated with a median follow-up time of 2.2 years. This study reported no significant differences in symptomatic...
Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.
13/07/2021
/
Publications
/
Toxicity
Survival
Twenty adults with medulloblastoma (≥ 22 years old) received postoperative proton CSI. This study reported no acute ≥ grade 3 gastrointestinal or hematologic...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.